Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, 5 South Zhongguancun Street, Beijing, 100081, China; CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Antimicrobial Agents, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, 5 South Zhongguancun Street, Beijing, 100081, China.
Talanta. 2024 Jun 1;273:125837. doi: 10.1016/j.talanta.2024.125837. Epub 2024 Mar 2.
CRISPR/Cas9 is a natural immune system of archaea and bacteria, which has been widely used in gene editing. In order to better control and improve the accuracy and safety of the system, inhibitors for SpyCas9 as "switches" have been selected for several years. The available inhibitors currently are all natural polypeptides inhibitors derived from phages, except one small molecule inhibitor. These natural inhibitors are challenging to obtain and are available in limited quantities, and the small molecule inhibitor is cytotoxic. Herein, we discover aptamers against the SpyCas9 protein, by coupling CE-SELEX within one-round pressure controllable selection strategy. One of the identified aptamers, Apt2, shows high affinity at the nanomolar level and leads for effective SpyCas9 enzymatic inhibition in vitro. It is predicted that Apt2 interacts with the HNH and RuvC domains of SpyCas9, competitively inhibiting the binding of substrate DNA to SpyCas9. The proposed aptamer inhibitor is the oligonucleotide inhibitor of SpyCas9, which has the potential in construction of the universal, simple and precise CRISPR-Cas9 system activity control strategy. Meanwhile, these aptamers could also be valuable tools for study of the functions of CRISPR/Cas9 and the related functional mechanisms.
CRISPR/Cas9 是古菌和细菌的一种天然免疫系统,已被广泛应用于基因编辑。为了更好地控制和提高该系统的准确性和安全性,人们已经选择了几种 SpyCas9 的抑制剂作为“开关”。目前可用的抑制剂均为来自噬菌体的天然多肽抑制剂,只有一种小分子抑制剂。这些天然抑制剂难以获得且数量有限,而小分子抑制剂具有细胞毒性。在此,我们通过在一轮压力可控的选择策略中结合 CE-SELEX 发现了针对 SpyCas9 蛋白的适体。鉴定出的适体之一 Apt2 在纳摩尔水平具有高亲和力,并在体外有效抑制 SpyCas9 的酶活性。据预测,Apt2 与 SpyCas9 的 HNH 和 RuvC 结构域相互作用,竞争性抑制底物 DNA 与 SpyCas9 的结合。所提出的适体抑制剂是 SpyCas9 的寡核苷酸抑制剂,有望构建通用、简单、精确的 CRISPR-Cas9 系统活性控制策略。同时,这些适体也可能是研究 CRISPR/Cas9 及其相关功能机制的有价值的工具。